Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "]] for current regimens." to "]] for regimens that include active anticancer treatment.") |
m |
||
| Line 10: | Line 10: | ||
==Placebo== | ==Placebo== | ||
| − | + | <div class="toccolours" style="background-color:#eeeeee"> | |
| − | |||
===Regimen=== | ===Regimen=== | ||
{| class="wikitable sortable" style="width: 100%; text-align:center;" | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| Line 23: | Line 22: | ||
|NR | |NR | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
| − | |[[Cutaneous_T-cell_lymphoma#Denileukin_diftitox_monotherapy|Denileukin diftitox]] | + | |1. [[Cutaneous_T-cell_lymphoma#Denileukin_diftitox_monotherapy|Denileukin diftitox]]; 9 mcg/kg<br>2. [[Cutaneous_T-cell_lymphoma#Denileukin_diftitox_monotherapy|Denileukin diftitox]]; 18 mcg/kg |
| style="background-color:#d73027" |Inferior PFS | | style="background-color:#d73027" |Inferior PFS | ||
|- | |- | ||
|} | |} | ||
| + | ''No active anticancer treatment.'' | ||
| + | </div> | ||
===References=== | ===References=== | ||
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | <!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL; and the 44th Annual Meeting of the American Society of Clinical Oncology, May 30-June 3, 2008, Chicago, IL. --> | ||
Revision as of 23:13, 29 October 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main CTCL page for regimens that include active anticancer treatment.
Relapsed or refractory
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase 3 (C) | 1. Denileukin diftitox; 9 mcg/kg 2. Denileukin diftitox; 18 mcg/kg |
Inferior PFS |
No active anticancer treatment.
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains dosing details in manuscript PubMed NCT00050999